$COCH
Envoy Medical, Inc. Stock $coch

$coch Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000110465923040842 Filed on April 03, 2023

Income Statement

Concept	2022 Q4	2022
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue		$498.0K
YoY Change
Gross Profit		-$498.0K
YoY Change
Gross Profit Margin
Selling, General & Admin		$2.585M
YoY Change
% of Gross Profit
Research & Development		$4.975M
YoY Change
% of Gross Profit
Depreciation & Amortization		$75.00K
YoY Change
% of Gross Profit
Operating Expenses	$1.465M	$4.888M
YoY Change	52.01%	-6.09%
Operating Profit		-$4.888M
YoY Change		-6.09%
Interest Expense	$4.390M	$26.12M
YoY Change	-210.08%	374.66%
% of Operating Profit
Other Income/Expense, Net	-$4.074M	-$498.8K
YoY Change	-1850.21%	-9.31%
Pretax Income	-$1.149M	$20.74M
YoY Change	-75.65%	-8340.44%
Income Tax	$859.4K	$1.502M
% Of Pretax Income		7.24%
Net Earnings	-$2.009M	$19.23M
YoY Change	-57.44%	-7743.56%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.57
Diluted Earnings Per Share	-$0.04	$0.36
COMMON SHARES
Basic Shares Outstanding		10.12M shares
Diluted Shares Outstanding		10.12M shares

Balance Sheet

Concept	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$107.8K	$107.8K
YoY Change	-28.08%	-28.08%
Cash & Equivalents	$107.8K
Short-Term Investments
Other Short-Term Assets	$112.7K	$112.7K
YoY Change	-84.21%	-84.21%
Inventory	$1.295M
Prepaid Expenses	$112.6K
Receivables	$41.00K
Other Receivables
Total Short-Term Assets	$220.4K	$220.4K
YoY Change	-74.46%	-74.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$331.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$430.0M	$430.0M
YoY Change	1.18%	1.18%
Other Assets	$353.7K	$353.7K
YoY Change	-64.73%	-64.73%
Total Long-Term Assets	$430.4M	$430.4M
YoY Change	1.02%	1.02%
TOTAL ASSETS
Total Short-Term Assets	$220.4K	$220.4K
Total Long-Term Assets	$430.4M	$430.4M
Total Assets	$430.6M	$430.6M
YoY Change	0.87%	0.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.178M	$1.178M
YoY Change	90.31%	90.31%
Accrued Expenses	$3.946M	$3.946M
YoY Change	91.59%	91.59%
Deferred Revenue
YoY Change
Short-Term Debt	$1.500M	$1.500M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.310M	$7.310M
YoY Change	172.94%	172.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$11.48M	$11.48M
YoY Change	-68.06%	-68.06%
Total Long-Term Liabilities	$11.48M	$11.48M
YoY Change	-68.06%	-68.06%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.310M	$7.310M
Total Long-Term Liabilities	$11.48M	$11.48M
Total Liabilities	$18.79M	$18.79M
YoY Change	-51.35%	-51.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.92M
YoY Change	-51.2%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$17.91M	$411.8M
YoY Change
Total Liabilities & Shareholders Equity	$430.6M	$430.6M
YoY Change	0.87%	0.87%

Cashflow Statement

Concept	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.009M	$19.23M
YoY Change	-57.44%	-7743.56%
Depreciation, Depletion And Amortization		$75.00K
YoY Change
Cash From Operating Activities	-$842.6K	-$2.658M
YoY Change	-4.81%	-18.0%
INVESTING ACTIVITIES
Capital Expenditures		$218.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$648.4K	$1.116M
YoY Change		-100.26%
Cash From Investing Activities	$648.4K	$1.116M
YoY Change		-100.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	1.500M
YoY Change	-100.0%	-99.65%
NET CHANGE
Cash From Operating Activities	-842.6K	-2.658M
Cash From Investing Activities	648.4K	1.116M
Cash From Financing Activities	0.000	1.500M
Net Change In Cash	-194.2K	-42.07K
YoY Change	-77.98%	-133.7%
FREE CASH FLOW
Cash From Operating Activities	-$842.6K	-$2.658M
Capital Expenditures		$218.0K
Free Cash Flow		-$2.876M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001840877
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	anzuu	Transition Report TransitionReport	false
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022	anzuu	Trading Day Period TradingDayPeriod	P10D
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40133
CY2022	dei	Entity Registrant Name EntityRegistrantName	Anzu Special Acquisition Corp I
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-1369123
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	12610 Race Track Road
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 250
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Tampa
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33626
CY2022	dei	City Area Code CityAreaCode	202
CY2022	dei	Local Phone Number LocalPhoneNumber	742-5870
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	true
CY2022Q2	dei	Entity Public Float EntityPublicFloat	416000000
CY2022	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2022	dei	Auditor Location AuditorLocation	New York, New York
CY2022	dei	Auditor Firm AuditorFirmId	100
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	107773
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149845
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	112649
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	713322
CY2022Q4	us-gaap	Assets Current AssetsCurrent	220422
CY2021Q4	us-gaap	Assets Current AssetsCurrent	863167
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	430047193
CY2021Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	425037665
CY2022Q4	anzuu	Forward Purchase Agreements Assets ForwardPurchaseAgreementsAssets	353731
CY2021Q4	anzuu	Forward Purchase Agreements Assets ForwardPurchaseAgreementsAssets	1002789
CY2022Q4	us-gaap	Assets Assets	430621346
CY2021Q4	us-gaap	Assets Assets	426903621
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1177546
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	618742
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3945680
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2059431
CY2022Q4	anzuu	Working Capital Loan WorkingCapitalLoan	1500000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	686530
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7309756
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2678173
CY2022Q4	anzuu	Deferred Underwriters Discount DeferredUnderwritersDiscount	10412500
CY2021Q4	anzuu	Deferred Underwriters Discount DeferredUnderwritersDiscount	14875000
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	1066667
CY2021Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	21063972
CY2022Q4	us-gaap	Liabilities Liabilities	18788923
CY2021Q4	us-gaap	Liabilities Liabilities	38617145
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17915833
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36714587
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-17914770
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-36713524
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	430621346
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	426903621
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	4888124
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5204970
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4888124
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-5204970
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	6125038
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	37665
CY2022	anzuu	Increase Decrease In Deferred Offering Costs Forgiveness IncreaseDecreaseInDeferredOfferingCostsForgiveness	150262
CY2021	anzuu	Increase Decrease In Deferred Offering Costs IncreaseDecreaseInDeferredOfferingCosts	782812
CY2022	anzuu	Change In Fair Value Of Forward Purchase Agreements ChangeInFairValueOfForwardPurchaseAgreements	649058
CY2021	anzuu	Change In Fair Value Of Forward Purchase Agreements ChangeInFairValueOfForwardPurchaseAgreements	-232789
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19997306
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5465695
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	20735424
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-251633
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1501714
CY2022	us-gaap	Net Income Loss NetIncomeLoss	19233710
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-251633
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-36713524
CY2022	us-gaap	Profit Loss ProfitLoss	19233710
CY2022	anzuu	Increase In Redemption Value Of Class Common Stock Subject To Redemption Due To Deemed Dividend IncreaseInRedemptionValueOfClassCommonStockSubjectToRedemptionDueToDeemedDividend	434956
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-17914770
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	24299
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	37256190
CY2021	anzuu	Proceeds From Issuance Of Forward Purchase Securities ProceedsFromIssuanceOfForwardPurchaseSecurities	770000
CY2021	us-gaap	Profit Loss ProfitLoss	-251633
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-36713524
CY2022	us-gaap	Profit Loss ProfitLoss	19233710
CY2021	us-gaap	Profit Loss ProfitLoss	-251633
CY2022	anzuu	Amortization Of Prepaid Assets AmortizationOfPrepaidAssets	704857
CY2021	anzuu	Amortization Of Prepaid Assets AmortizationOfPrepaidAssets	499699
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19997306
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5465695
CY2022	anzuu	Gain From Extinguishment Of Deferred Underwriting Commissions Allocated To Derivative Warrant Liabilities GainFromExtinguishmentOfDeferredUnderwritingCommissionsAllocatedToDerivativeWarrantLiabilities	150262
CY2022	anzuu	Fair Value Adjustment Forward Purchase Agreements FairValueAdjustmentForwardPurchaseAgreements	-649058
CY2021	anzuu	Fair Value Adjustment Forward Purchase Agreements FairValueAdjustmentForwardPurchaseAgreements	232789
CY2021	anzuu	Offering Costs Allocated To Warrant Liabilities OfferingCostsAllocatedToWarrantLiabilities	782812
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	6125038
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	37665
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	104184
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1213021
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	558804
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	618040
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1886249
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2059431
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	686530
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2657582
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3240821
CY2022	anzuu	Proceeds From Payments For Withdrawal From Investment Of Funds In Trust Account ProceedsFromPaymentsForWithdrawalFromInvestmentOfFundsInTrustAccount	1115510
CY2021	anzuu	Proceeds From Payments For Withdrawal From Investment Of Funds In Trust Account ProceedsFromPaymentsForWithdrawalFromInvestmentOfFundsInTrustAccount	-425000000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1115510
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-425000000
CY2021	anzuu	Net Proceeds From Initial Public Offering NetProceedsFromInitialPublicOffering	425000000
CY2021	anzuu	Proceeds From Sale Of Private Warrants ProceedsFromSaleOfPrivateWarrants	12500000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9134334
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1500000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1500000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	428365666
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42072
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	124845
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	149845
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107773
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	149845
CY2021	anzuu	Deferred Underwriting Commissions DeferredUnderwritingCommissions	14875000
CY2021	anzuu	Deferred Offering Costs Included In Accounts Payable DeferredOfferingCostsIncludedInAccountsPayable	-94992
CY2021	anzuu	Deferred Offering Cost Associated With Proposed Public Offering DeferredOfferingCostAssociatedWithProposedPublicOffering	94992
CY2022	anzuu	Temporary Equity Accretion To Redemption Amount TemporaryEquityAccretionToRedemptionAmount	-434956
CY2021	anzuu	Temporary Equity Accretion To Redemption Amount TemporaryEquityAccretionToRedemptionAmount	-37256190
CY2021	anzuu	Initial Classification Of Forward Purchase Agreements InitialClassificationOfForwardPurchaseAgreements	-770000
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1 - Organization and Business Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Organization and General</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Anzu Special Acquisition Corp I (the “Company”) is a blank check company incorporated as a Delaware corporation on December 28, 2020 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (a “Business Combination”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While the Company may pursue a Business Combination target in any industry, the Company currently intends to concentrate its efforts in identifying high-quality businesses with transformative technologies. Since completing the Company’s initial public offering (the “IPO” or the “Initial Public Offering”), the Company has reviewed, and continues to review, a number of opportunities to enter into a Business Combination with an operating business, but the Company is not able to determine at this time whether it will complete a Business Combination with any of the target businesses that the Company has reviewed or with any other target business. The Company intends to effectuate a Business Combination using cash from the proceeds of the IPO and the sale of the Private Placement Warrants (as defined below), the Company’s capital stock, debt, or a combination of cash, stock and debt.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had not commenced any operations. All activity through December 31, 2022 relates to the Company’s formation and the IPO described below, and, subsequent to the IPO, identifying a target company for a Business Combination. The Company does not expect to generate any operating revenues until after the completion of a Business Combination. The Company generates non-operating income in the form of interest income on marketable securities held in the Trust Account (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s sponsor is Anzu SPAC GP I LLC, a Delaware limited liability company (the “Sponsor”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 4, 2021, the Company consummated the IPO of 42,000,000 units (the “Units” and, with respect to the shares of Class A common stock included in the Units, the “public shares”) and, on April 14, 2021, the Company issued an additional 500,000 Units in connection with the underwriters’ partial exercise of their over-allotment option. Each Unit consists of one share of the Company’s Class A common stock, par value $0.0001 per share, and one-third of one warrant (the “Public Warrants”) of the Company, with each whole warrant entitling the holder thereof to purchase one whole share of Class A common stock at a price of $11.50 per share, subject to certain adjustments. The Units were sold at a price of $10.00 per unit, generating aggregate gross proceeds to the Company of $425,000,000 (see Note 4 and Note 8).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the IPO, the Company completed the private sale (the “Private Placement”) of 12,400,000 warrants (the “Private Placement Warrants”) to the Sponsor and, on April 14, 2021, simultaneously with the closing of the underwriters’ over-allotment option, the Company issued an additional 100,000 Private Placement Warrants to the Sponsor. The Private Placement Warrants were sold at a price of $1.00 per Private Placement Warrant, generating aggregate gross proceeds of $12,500,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Transaction costs of the IPO prior to the underwriters’ partial exercise of their over-allotment option amounted to $23,731,835, consisting of $8,400,000 of underwriting commissions, $14,700,000 of deferred underwriters’ commissions and $631,835 of other offering costs. Offering costs associated with the closing of the underwriters’ over-allotment option on April 14, 2021 amounted to $280,500, consisting of $100,000 of underwriting commissions, $175,000 of deferred underwriters’ commissions and $5,500 of other offering costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Trust Account</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Following the closing of the IPO on March 4, 2021, $420,000,000 ($10.00 per Unit) from the net proceeds of the sale of the Units in the IPO and the sale of the Private Placement Warrants was placed in a U.S.-based trust account (the “Trust Account”). Following the closing of the underwriters’ over-allotment option on April 14, 2021, an additional $5,000,000 ($10.00 per Unit) from </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the net proceeds of the sale of the additional Units and Private Placement Warrants was placed in the Trust Account. The funds in the Trust Account are invested in a money market fund investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company Act of 1940, as amended. The Company will not be permitted to withdraw any of the principal or interest held in the Trust Account except for the withdrawal of interest to pay taxes, if any. The funds held in the Trust Account will not otherwise be released from the Trust Account until the earliest of (1) the Company’s completion of a Business Combination; (2) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with a Business Combination or to redeem 100% of the public shares if the Company does not complete a Business Combination within 24 months from the closing of the IPO or (B) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity; and (3) the redemption of the Company’s public shares if the Company has not completed a Business Combination by September 30, 2023 or such earlier date as determined by the Company’s board of directors, subject to applicable law. Based on current interest rates, the Company expects that interest earned on the Trust Account will be sufficient to pay taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Business Combination</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s management has broad discretion with respect to the specific application of the net proceeds from the IPO, although substantially all of the net proceeds from the IPO are intended to be generally applied toward consummating a Business Combination with (or acquisition of) a Target Business. As used herein, “Target Business” means one or more target businesses that together have an aggregate fair market value equal to at least 80% of the value of the assets held in the Trust Account (excluding taxes payable on the interest earned on the Trust Account) at the time of the signing of a definitive agreement in connection with a Business Combination. Furthermore, there is no assurance that the Company will be able to successfully effect a Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company will provide its public stockholders with the opportunity to redeem all or a portion of their public shares upon the completion of a Business Combination, either (i) in connection with a stockholder meeting called to approve such Business Combination or (ii) by means of a tender offer. The public stockholders will be entitled to redeem their shares for a pro rata portion of the amount held in the Trust Account, calculated as of two business days prior to the completion of a Business Combination, including any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations. The per-share amount to be distributed to the public stockholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 7). There will be no redemption rights upon the completion of a Business Combination with respect to the Company’s warrants. As a result, shares of common stock were recorded at their redemption amount and classified as temporary equity upon the completion of the IPO, in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity” (“ASC 480”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The decision as to whether the Company will seek stockholder approval of a Business Combination or will allow stockholders to sell their shares in a tender offer will be made by the Company, in its sole discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would otherwise require the Company to seek stockholder approval unless a vote is required by law or stock exchange listing requirements. If the Company seeks stockholder approval, it will complete its Business Combination only if a majority of the shares of common stock voted are voted in favor of a Business Combination. However, in no event will the Company redeem its public shares in an amount that would cause its net tangible assets to be less than $5,000,001 upon consummation of a Business Combination. In such case, the Company would not proceed with the redemption of its public shares of common stock and the related Business Combination, and instead may search for an alternate Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has until September 30, 2023 or such earlier date as determined by the Company’s board of directors (or such longer period as provided in an amendment to the Company’s amended and restated certificate of incorporation approved by the Company’s stockholders (an “Extension Period”)) to complete its initial Business Combination. If the Company does not complete a Business Combination by September 30, 2023 or such earlier date as determined by the Company’s board of directors, or during any Extension Period, it shall (i) cease all operations except for the purposes of winding up; (ii) as promptly as reasonably possible but not more than 10 business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">shall be net of taxes payable), divided by the number of then issued and outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and its board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company’s warrants, which will expire worthless if it fails to complete its initial Business Combination by September 30, 2023 or such earlier date as determined by the Company’s board of directors, or during any Extension Period. The initial stockholders (the Sponsor and the three directors that hold Founder Shares (as defined in Note 6) have entered into a letter agreement with the Company, pursuant to which they have waived their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if the Company fails to complete its initial Business Combination by September 30, 2023 or such earlier date as determined by the Company’s board of directors, or during any Extension Period. However, if the initial stockholders acquire public shares, they will be entitled to liquidating distributions from the Trust Account with respect to such public shares if the Company fails to complete its initial Business Combination within the allotted time frame.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be less than $10.00 per public share initially held in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per public share or (2) such lesser amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in value of the trust assets, in each case net of the amount of interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act. In the event that an executed waiver is deemed to be unenforceable against a third party, then the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to have all third parties, including, but not limited to, all vendors, service providers (other than its independent registered public accounting firm), prospective target businesses and other entities with which the Company does business execute agreements with the Company waiving any right, title, interest or claims of any kind in or to any monies held in the Trust Account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks and Uncertainties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy is not determinable as of the date of these financial statements. The specific impact on the Company’s financial condition, results of operations, and cash flows is also not determinable as of the date of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 10, 2023 Silicon Valley Bank became insolvent. State regulators closed the bank and the Federal Deposit Insurance Corporation (“FDIC”) was appointed as its receiver. The Company held deposits with this bank. As a result of the actions by the FDIC, the Company’s insured and uninsured deposits have been restored.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022 and 2021, the Company had $107,773 and $149,845 in its operating bank accounts, respectively, and working capital deficits of $(7,089,334) and $(1,815,006), respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the completion of the Initial Business Combination, the Company’s liquidity needs had been satisfied through a contribution of $25,000 from Sponsor to cover for certain formation and offering costs in exchange for the issuance of the Founder Shares, the loan of up to $300,000 from the Sponsor pursuant to the Note (see Note 6), and the proceeds from the consummation of the Private Placement not held in the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (see Note 6). As of December 31, 2022 and 2021, there were amounts of $1,500,000 and $0 outstanding under the Working Capital Loans, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may need to raise additional funds through loans from its Sponsor and/or third parties in order to meet the expenditures required for operating its business. If the Company’s estimate of the costs of undertaking in-depth due diligence and negotiating the initial business combination is less than the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to the initial business combination. The Sponsor is not under any obligation to advance funds to, or to invest in, the Company. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of its business plan, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. If a Business Combination is not consummated by September 30, 2023 or such earlier date as determined by the Company’s board of directors, or during any Extension Period, there will be a mandatory liquidation and subsequent dissolution of the Company. Mandatory liquidation and liquidity condition raise substantial doubt about the Company’s ability to continue as a going concern through one year from the date of these financial statements if a Business Combination is not consummated. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management plans to complete a Business Combination prior to the mandatory liquidation date and expects to receive financing to meet its obligations through the time of liquidation; however no financing is currently committed. The financial statements do not include any adjustment that might be necessary if we are unable to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p>
CY2020Q4	anzuu	Condition For Future Business Combination Number Of Businesses Minimum ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum	1
CY2020Q4	anzuu	Transaction Costs TransactionCosts	23731835
CY2020Q4	anzuu	Sale Of Stock Underwriting Fees SaleOfStockUnderwritingFees	8400000
CY2020Q4	anzuu	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	14700000
CY2020Q4	anzuu	Sale Of Stock Other Offering Costs SaleOfStockOtherOfferingCosts	631835
CY2022	anzuu	Redemption Percentage Required If Business Combination Is Not Completed By Specified Date RedemptionPercentageRequiredIfBusinessCombinationIsNotCompletedBySpecifiedDate	1
CY2022	anzuu	Threshold Business Combination Fmv As Percent Of Trust Assets ThresholdBusinessCombinationFmvAsPercentOfTrustAssets	0.80
CY2022	anzuu	Minimum Tangible Assets Of Target MinimumTangibleAssetsOfTarget	5000001
CY2022	anzuu	Redemption Period Upon Closure RedemptionPeriodUponClosure	P10D
CY2022	anzuu	Maximum Allowed Dissolution Expenses MaximumAllowedDissolutionExpenses	100000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	107773
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149845
CY2022	anzuu	Working Capital Deficit WorkingCapitalDeficit	-7089334
CY2021	anzuu	Working Capital Deficit WorkingCapitalDeficit	-1815006
CY2022	anzuu	Proceeds From Related Party For Expense Payments In Exchange For Shares Issued ProceedsFromRelatedPartyForExpensePaymentsInExchangeForSharesIssued	25000
CY2022Q4	anzuu	Maximum Borrowing Capacity Of Related Party Promissory Note MaximumBorrowingCapacityOfRelatedPartyPromissoryNote	300000
CY2022Q3	anzuu	Increase Decrease In Deferred Offering Costs Forgiveness IncreaseDecreaseInDeferredOfferingCostsForgiveness	150263
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1378113
	anzuu	Increase Decrease In Deferred Offering Costs Forgiveness IncreaseDecreaseInDeferredOfferingCostsForgiveness	150263
	us-gaap	Net Income Loss NetIncomeLoss	16930212
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	1378113
CY2022Q3	anzuu	Forgiveness Of Deferred Underwriting Fess Recorded In Accumulated Deficit ForgivenessOfDeferredUnderwritingFessRecordedInAccumulatedDeficit	2722935
	us-gaap	Profit Loss ProfitLoss	16930212
	anzuu	Gain On Forgiveness Of Deferred Offering Costs GainOnForgivenessOfDeferredOfferingCosts	150263
	anzuu	Extinguishment Of Deferred Underwriting Commissions Allocated To Public Shares ExtinguishmentOfDeferredUnderwritingCommissionsAllocatedToPublicShares	4312237
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgement. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.</p>
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p>
CY2022Q4	anzuu	Transaction Costs TransactionCosts	782812
CY2022Q4	anzuu	Sale Of Stock Underwriting Fees SaleOfStockUnderwritingFees	762300
CY2022Q4	anzuu	Sale Of Stock Other Offering Costs SaleOfStockOtherOfferingCosts	20512
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	94992
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q1	anzuu	Number Of Shares Issued Per Unit NumberOfSharesIssuedPerUnit	1
CY2022Q4	anzuu	Maximum Number Of Demands For Registration Of Securities MaximumNumberOfDemandsForRegistrationOfSecurities	3
CY2021Q1	anzuu	Underwriter Cash Discount UnderwriterCashDiscount	8400000
CY2021Q2	anzuu	Underwriter Cash Discount UnderwriterCashDiscount	100000
CY2022Q4	anzuu	Deferred Fee Per Unit DeferredFeePerUnit	0.35
CY2022	anzuu	Aggregate Deferred Underwriting Fee Payable AggregateDeferredUnderwritingFeePayable	14875000
CY2022	anzuu	Forgiveness Of Deferred Underwriting Fess ForgivenessOfDeferredUnderwritingFess	4462500
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	100000000
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2022	anzuu	Temporary Equity Number Of Votes Per Share TemporaryEquityNumberOfVotesPerShare	1
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	42500000
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	42500000
CY2022Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.11
CY2022	anzuu	Proceeds From Issuance Of Temporary Equity ProceedsFromIssuanceOfTemporaryEquity	429747193
CY2021Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.00
CY2021	anzuu	Proceeds From Issuance Of Temporary Equity ProceedsFromIssuanceOfTemporaryEquity	425000000
CY2021	anzuu	Proceeds From Issuance Of Temporary Equity ProceedsFromIssuanceOfTemporaryEquity	425000000
CY2021	anzuu	Temporary Equity Proceeds Allocated To Warrants TemporaryEquityProceedsAllocatedToWarrants	-14026667
CY2021	anzuu	Temporary Equity Issuance Costs TemporaryEquityIssuanceCosts	-23229523
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	37256190
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	425000000
CY2022	anzuu	Waiver Of Class Shares Issuance Costs WaiverOfClassSharesIssuanceCosts	4312237
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	434956
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	429747193
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022	anzuu	Fair Value Recurring Basis Unobservable Input Reconciliation Asset Gain Loss Statement Of Income Extensible List Not Disclosed Flag FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleListNotDisclosedFlag	true
CY2022	anzuu	Warrants Will Expire WarrantsWillExpire	P5Y
CY2022	anzuu	Proceeds From Repurchase Of Equity Percentage ProceedsFromRepurchaseOfEquityPercentage	60
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	26666666
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1175834
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	325880
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2077550
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1085134
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-429855
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2507405
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1085134
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1501714
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7910
CY2022Q4	anzuu	Deferred Tax Assets Capitalized Start Up And Organization Costs DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts	-2507405
CY2021Q4	anzuu	Deferred Tax Assets Capitalized Start Up And Organization Costs DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts	-1093044
CY2022Q4	anzuu	Deferred Income Tax Assets Gross DeferredIncomeTaxAssetsGross	-2507405
CY2021Q4	anzuu	Deferred Income Tax Assets Gross DeferredIncomeTaxAssetsGross	-1085134
CY2022Q4	anzuu	Deferred Income Tax Assets Valuation Allowance DeferredIncomeTaxAssetsValuationAllowance	-2507405
CY2021Q4	anzuu	Deferred Income Tax Assets Valuation Allowance DeferredIncomeTaxAssetsValuationAllowance	-1085134
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	anzuu	Effective Income Tax Rate Reconciliation At Cost Allocated To Warrants Percent EffectiveIncomeTaxRateReconciliationAtCostAllocatedToWarrantsPercent	0.0000
CY2021	anzuu	Effective Income Tax Rate Reconciliation At Cost Allocated To Warrants Percent EffectiveIncomeTaxRateReconciliationAtCostAllocatedToWarrantsPercent	0.6533
CY2022	anzuu	Change In Deferred Offering Costs ChangeInDeferredOfferingCosts	-0.0015
CY2021	anzuu	Change In Deferred Offering Costs ChangeInDeferredOfferingCosts	0.0000
CY2022	anzuu	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liabilities Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilitiesPercent	-0.2025
CY2021	anzuu	Effective Income Tax Rate Reconciliation Change In Fair Value Of Warrant Liabilities Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantLiabilitiesPercent	-4.5614
CY2022	anzuu	Effective Income Tax Rate Reconciliation Change In Fair Value Of Forward Purchase Agreements Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfForwardPurchaseAgreementsPercent	0.0066
CY2021	anzuu	Effective Income Tax Rate Reconciliation Change In Fair Value Of Forward Purchase Agreements Percent EffectiveIncomeTaxRateReconciliationChangeInFairValueOfForwardPurchaseAgreementsPercent	-0.1943
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0682
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	3.8924
CY2022	anzuu	Income Tax Reconciliation Other Adjustment IncomeTaxReconciliationOtherAdjustment	-0.0084
CY2021	anzuu	Income Tax Reconciliation Other Adjustment IncomeTaxReconciliationOtherAdjustment	0.0000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0724
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023Q2	us-gaap	Notes Payable NotesPayable	734300

Files In Submission

Name	View Source	Status
anzuu-20221231_lab.xml	Edgar Link	unprocessable
0001104659-23-040842-index-headers.html	Edgar Link	pending
0001104659-23-040842-index.html	Edgar Link	pending
0001104659-23-040842.txt	Edgar Link	pending
0001104659-23-040842-xbrl.zip	Edgar Link	pending
anzuu-20221231.xsd	Edgar Link	pending
anzuu-20221231x10k.htm	Edgar Link	pending
anzuu-20221231xex10d13.htm	Edgar Link	pending
anzuu-20221231xex10d14.htm	Edgar Link	pending
anzuu-20221231xex31d1.htm	Edgar Link	pending
anzuu-20221231xex31d2.htm	Edgar Link	pending
anzuu-20221231xex32d1.htm	Edgar Link	pending
anzuu-20221231xex32d2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
anzuu-20221231_cal.xml	Edgar Link	unprocessable
anzuu-20221231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
anzuu-20221231_pre.xml	Edgar Link	unprocessable
anzuu-20221231x10k_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$COCH
Envoy Medical, Inc. Stock $coch

2022 Q4 Form 10-K Financial Statement

#000110465923040842 Filed on April 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COCH Envoy Medical, Inc. Stock $coch

2022 Q4 Form 10-K Financial Statement

#000110465923040842 Filed on April 03, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$COCH
Envoy Medical, Inc. Stock $coch